Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database
ICIs may have a significant association with the occurrence of pancreatitis. In clinical applications, it is necessary to closely monitor the indicators related to pancreatitis in patients, such as abdominal pain, nausea, vomiting, elevated serum amylase or lipase, and take timely intervention measures to reduce the risk of complications.
Authors
- Lingli Huang (ORCID: https://orcid.org/0000-0002-6686-5942)
- Maggie Haitian Wang (ORCID: https://orcid.org/0000-0003-1223-4595)
- Nan Wu (ORCID: https://orcid.org/0000-0003-0942-5278)
Institutions
- Jiangsu Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.3389/fphar.2025.1635372
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Jiangsu Cancer Hospital